AST-004 (Ascentawits Pharmaceuticals Ltd.)

AST-004 is a preclinical small molecule targeted conjugate drug (SMDC) being developed by Ascentawits Pharmaceuticals for the treatment of colorectal cancer. Utilizing the company's proprietary platform, AST-004 consists of a small-molecule targeting fragment conjugated to a cytotoxic or chemotherapy payload. This design is intended to selectively deliver the therapeutic agent to tumor cells, thereby increasing efficacy and reducing systemic toxicity compared to traditional chemotherapy. As of early 2024, the drug is in the preclinical registration study phase, and its specific molecular target remains confidential.